Should I buy United Therapeutics (UTHR) stock or is it too late?
⭐ The most reliable of them, either direction: BTIG — 63% of its targets hit on this sector (41 calls tested). It aims for $728 (+34 %), call made on October 2, 2026, maturing on October 2, 2027 (12 d ago).
Firm-by-firm track record on United Therapeutics
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Ladenburg Thalmann | 100 % | +29.1 % | 8 | $344 -37% |
| JP Morgan | 58 % | +27.4 % | 12 | $687 +26% |
| UBS | 78 % | +27.3 % | 9 | $705 +30% |
| Wedbush | 70 % | +26.1 % | 10 | $308 -43% |
| HC Wainwright & Co. | 60 % | +24.6 % | 15 | $660 +21% |
| Jefferies | 80 % | +24.6 % | 5 | $564 +4% |
| Oppenheimer | 62 % | +12.4 % | 8 | $600 +10% |
| Morgan Stanley | 57 % | +12.1 % | 7 | $566 +4% |
✅ Reasons to believe
- Median price target $687, i.e. +26% from the current price ($543).
- The most reliable firm on UTHR, Cantor Fitzgerald (100% hit rate, 2 scored calls), targets $625 (call made on March 12, 2026, maturing on March 12, 2027) (+15%) in its most recent call.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 7 ratings, 2 are neutral and 1 is a sell.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on UTHR
Median target $687 (+26%) · 7 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in United Therapeutics now?
We won't decide for you. The facts: 57% of analysts rate it a buy, median target $687 (+26%), and Cantor Fitzgerald (most reliable on UTHR, 100%) targets $625. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in United Therapeutics?
Not according to analysts: the median target ($687) is still +26% above the current price ($543) (most reliable on UTHR: Cantor Fitzgerald, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is United Therapeutics still worth investing in?
It depends on the gap between the price ($543) and its estimated value: analysts target $687 on median (+26%), with 57% buys (most reliable on UTHR: Cantor Fitzgerald, 100%). Cross-check with their real reliability on UTHR and the cautions above. Information, not advice.
What's the main risk in buying UTHR?
The consensus is not unanimous: of 7 ratings, 2 are neutral and 1 is a sell.
→ Go deeper: the full United Therapeutics profile (consensus, analyst reliability, price target, performance).